Recent Updates
Recently added Catalysts
BVS Negative Sentiment Score: 20/100

Bioventus Inc Investors: Please contact the Portnoy Law Firm to recover your losses

Key Takeaway: The Portnoy Law Firm has initiated an investigation into Bioventus Inc on behalf of investors who have suffered financial losses. Bioventus recently faced challenges, including filing for an extension on its quarterly report due to issues with a major payer in its pain treatments sector. This situation raised concerns about the company's internal controls and its ability to meet financial obligations. Following this news, Bioventus' stock saw a sharp decline during after-hours trading.

Market Sentiment Analysis

CONCERNS & RISKS

  • Bioventus Inc is facing an investigation due to significant financial losses reported by investors.
  • The company disclosed inadequate internal controls, which may affect its financial reporting.
  • There are concerns about the company's ability to meet financial obligations within the coming year.
  • The stock price declined sharply following negative news about financial performance.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Feb. 14, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bioventus Inc (“Bioventus”) (NASDAQ: BVS) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Bioventus stock. Bioventus investors are encouraged to contact the firm to discuss their legal rights.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On November 17, 2022, Bioventus filed for an extension to publish its quarterly report due to a contested invoice from a large private payer in the company’s pain treatments vertical, “which likely will adversely affect the company’s third quarter 2022 financial results.” Bioventus further disclosed that “management has concluded that its internal controls related to the timely recognition of quarterly rebates were inadequate.” The company also announced that is also evaluating whether it “will be able to meet all of its financial obligations as they come due within one year after the date its financial statements for the period ended October 1, 2022 are issued.”
On this news, Bioventus stock fell sharply during after-hours trading on November 17, 2022.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

How can Bioventus investors recover their losses?

Bioventus investors can contact the Portnoy Law Firm for a no-cost case evaluation.

Who can I contact for assistance with Bioventus losses?

Investors can reach attorney Lesley F. Portnoy at 844-767-8529 or via email.

What caused the decline in Bioventus stock?

The stock fell due to concerns over a contested invoice affecting financial results.

What issues did Bioventus disclose on November 17, 2022?

They disclosed inadequate internal controls and potential financial obligation challenges.

Is there a cost to evaluate my Bioventus case?

No, the Portnoy Law Firm offers a complimentary case evaluation for investors.

Last updated: Feb 14, 2023